Philogen Future Growth
Future criteria checks 2/6
Philogen's revenue and earnings are forecast to decline at 5% and 86.4% per annum respectively while EPS is expected to decline by 86.2% per annum.
Key information
-86.4%
Earnings growth rate
-86.2%
EPS growth rate
Biotechs earnings growth | 30.6% |
Revenue growth rate | -5.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 03 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 39 | -107 | -104 | -98 | 2 |
12/31/2025 | 21 | -46 | -51 | -45 | 2 |
12/31/2024 | 86 | 4 | 3 | 10 | 2 |
12/31/2023 | 25 | -6 | -11 | -5 | N/A |
9/30/2023 | 27 | -3 | -7 | -3 | N/A |
6/30/2023 | 29 | 0 | -3 | -1 | N/A |
3/31/2023 | 28 | -3 | -6 | -3 | N/A |
12/31/2022 | 27 | -5 | -9 | -5 | N/A |
9/30/2022 | 25 | -5 | -9 | -4 | N/A |
6/30/2022 | 23 | -5 | -9 | -2 | N/A |
3/31/2022 | 14 | -10 | -17 | -11 | N/A |
12/31/2021 | 5 | -16 | -26 | -19 | N/A |
9/30/2021 | 6 | -14 | -26 | -19 | N/A |
6/30/2021 | 6 | -14 | -25 | -18 | N/A |
3/31/2021 | 6 | -13 | -21 | -16 | N/A |
12/31/2020 | 6 | -13 | -17 | -13 | N/A |
9/30/2020 | 8 | -11 | -15 | -12 | N/A |
12/31/2019 | 15 | 1 | 6 | 7 | N/A |
12/31/2018 | 16 | 4 | 5 | 5 | N/A |
12/31/2017 | 14 | 3 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 78Q's earnings are forecast to decline over the next 3 years (-86.4% per year).
Earnings vs Market: 78Q is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 78Q is expected to become profitable in the next 3 years.
Revenue vs Market: 78Q's revenue is expected to decline over the next 3 years (-5% per year).
High Growth Revenue: 78Q's revenue is forecast to decline over the next 3 years (-5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 78Q's Return on Equity is forecast to be high in 3 years time